Study identifies how tamoxifen stimulates uterine cell growth and cancer
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth. The research is significant in helping determine why tamoxifen and other synthetic estrogens are linked to increased rates of endometriosis and uterine cancer, and identifies a pathway that could be targeted in drug therapies for those diseases, researchers say.
Findings are published in the July 1, 2009 issue of "Cancer Research," the journal of the American Association for Cancer Research. The paper also can be found online at http://cancerres.aacrjournals.org/current.shtml.
The research found that when activated by estrogens, endometrial cells obtained from patients suffering from endometriosis or human uterine cancer cells initiate a previously unknown cascade of signals that leads to cellular replication and further estrogen production, the paper says.
The ensuing cycle leads to abnormal growth of the cells lining the uterus, or endometrium, which occurs in endometriosis and uterine cancer, according to senior author Holly A. Ingraham, PhD, a professor in the UCSF School of Medicine's Department of Cellular and Molecular Pharmacology.
"It turns out that displaced endometrial cells, such as those used in this study, are estrogen factories," said Ingraham, who also is affiliated with the UCSF Helen Diller Family Comprehensive Cancer Center and the UCSF Center for Reproductive Sciences. "They pump out estrogen in a feed-forward pathway, so the more estrogen they produce, the more estrogen they're capable of producing."
While this pathway was previously unknown, Ingraham said a June 2009 paper led by researchers at the University of New Mexico and published in the journal "Nature Chemical Biology" showed that blocking the GPR30 receptor in this pathway decreases uterine proliferation in a mouse. The two together, she said, validate what researchers now think may be a key area in addressing both uterine cancer and endometriosis.
Uterine cancer is the fourth most common cancer in women, with more than 37,000 women being diagnosed each year in the United States alone, according to data from the Centers for Disease Control.
Endometriosis, in which endometrial cells grow in areas other than the uterus, is the most common gynecological disease and affects more than 5.5 million women in North America, according to the National Institutes of Health. The disease often causes severe pain and can lead to infertility.
Working in collaboration with clinicians at Northwestern University in Chicago, the UCSF team analyzed cells from women with ectopic endometriosis. By studying those patients' endometrial cells, the team was able to identify an unusual, circular pathway involving these cells, the transmembrane estrogen receptor GPR30 and the nuclear receptor SF-1.
The researchers propose that this pathway increases local concentrations of estrogen and, together with classic estrogen-receptor signaling, control the proliferative effects of these estrogens in promoting endometriosis and endometrial cancers.
The UCSF team used a unique chemical biology approach, making use of a tamoxifen-like compound developed in the laboratory of co-author Thomas Scanlan, PhD, who is affiliated with both the UCSF Department of Pharmaceutical Chemistry and the Department of Chemical Biology at the Oregon Health Sciences University in Portland.
"Tamoxifen and other synthetic estrogens have been known to increase the risk of uterine cancer, but until now, we didn't know why that was on a cellular level," Ingraham said. "We think this pathway is going to be an important one in solving that mystery."
- Previously unseen switch regulates breast cancer response to estrogenThu, 8 May 2008, 15:07:32 EDT
- A new take on growth factor signaling in tamoxifen resistanceTue, 23 Jun 2009, 19:38:33 EDT
- News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen responseWed, 25 Nov 2009, 20:14:49 EST
- Future hope for patients with breast cancers resistant to tamoxifenMon, 16 Jun 2008, 15:07:46 EDT
- Master gene SRC-3 enables breast cancer growth, invasionFri, 12 Feb 2010, 12:47:14 EST
Articles on the same topic
- Newly appreciated membrane estrogen receptor important therapeutic target for breast cancerWed, 1 Jul 2009, 14:57:36 EDT
- Study identifies how tamoxifen stimulates uterine cell growth and cancerfrom Science CentricThu, 2 Jul 2009, 21:42:09 EDT
- Study identifies how tamoxifen stimulates uterine cell growth and cancerfrom PhysorgThu, 2 Jul 2009, 17:56:03 EDT
- Newly appreciated membrane estrogen receptor important therapeutic target for breast cancerfrom PhysorgWed, 1 Jul 2009, 14:56:05 EDT
- New Take On Growth Factor Signaling In Tamoxifen Resistancefrom Science DailyTue, 30 Jun 2009, 10:21:12 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
No popular news yet
- From ocean to land: The fishy origins of our hips
- New method of finding planets scores its first discovery
- Invasive crazy ants are displacing fire ants in areas throughout southeastern US
- Seabird bones reveal changes in open-ocean food chain
- Scientific insurgents say 'Journal Impact Factors' distort science
No popular news yet
No popular news yet
- Stem cell transplant restores memory, learning in mice
- 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
- Researchers discover mushrooms can provide as much vitamin D as supplements
- Cutting back on sleep harms blood vessel function and breathing control
- Study: Low-dose aspirin stymies proliferation of 2 breast cancer lines